Contrasting Cytosorbents (NASDAQ:CTSO) & Caliber Imaging & Diagnostics (OTCMKTS:LCDX)

Caliber Imaging & Diagnostics (OTCMKTS:LCDX) and Cytosorbents (NASDAQ:CTSO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Caliber Imaging & Diagnostics and Cytosorbents, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caliber Imaging & Diagnostics	0	0	0	0	N/A
Cytosorbents	0	1	1	1	3.00

Cytosorbents has a consensus price target of $2.00, indicating a potential upside of 100.00%.

Earnings & Valuation

This table compares Caliber Imaging & Diagnostics and Cytosorbents”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caliber Imaging & Diagnostics	N/A	N/A	N/A	($0.75)	N/A
Cytosorbents	$36.35 million	1.50	-$28.51 million	($0.53)	-1.89

Caliber Imaging & Diagnostics has higher earnings, but lower revenue than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Caliber Imaging & Diagnostics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Caliber Imaging & Diagnostics and Cytosorbents’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caliber Imaging & Diagnostics	N/A	N/A	N/A
Cytosorbents	-68.70%	-131.84%	-50.72%

Insider & Institutional Ownership

32.9% of Cytosorbents shares are held by institutional investors. 6.6% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cytosorbents beats Caliber Imaging & Diagnostics on 6 of the 10 factors compared between the two stocks.

About Caliber Imaging & Diagnostics

Caliber Imaging & Diagnostics, Inc., a medical technologies company, designs, develops, and markets imaging solutions that shows tissue at the cellular level in the United States. The company provides VivaScope 1500, a reflectance confocal imaging system that enables clinicians and researchers to capture confocal images that depict cellular structures of living tissue; and VivaScope 3000, a hand-held in vivo reflectance confocal microscope for skin imaging. It also offers VivaScan software to schedule patients for examinations, perform imaging examinations on one or more lesions during a visit, review, and report on images obtained during an examination, as well as VivaNet, a digital telepathology system. The company was formerly known as Lucid, Inc. and changed its name to Caliber Imaging & Diagnostics, Inc. in August 2012. Caliber Imaging & Diagnostics, Inc. was founded in 1991 and is headquartered in Andover, Massachusetts.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.